Drug
Sar402663
Sar402663: highest development phase Phase 1/2, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAR402663 NCT06660667 | Phase 1/2 | Neovascular Age-related Macular Degeneration |
Latest
No recent events.
Follow Sar402663 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.